{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:04:03Z","timestamp":1785553443615,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472924"],"award-info":[{"award-number":["82472924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404059"],"award-info":[{"award-number":["82404059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3402700"],"award-info":[{"award-number":["2023YFC3402700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtho.2025.04.014","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T19:25:16Z","timestamp":1746213916000},"page":"1120-1130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Shuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-3141","authenticated-orcid":false,"given":"Jianyong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.04.014_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2025.04.014_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M116.064675","article-title":"A two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life","volume":"16","author":"Jensen","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jtho.2025.04.014_bib3","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2025.04.014_bib4","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2025.04.014_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtho.2025.04.014_bib6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jtho.2025.04.014_bib7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jtho.2025.04.014_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/JS9.0000000000001981","article-title":"A new pragmatic classification system for thymoma-associated myasthenia gravis: a retrospective cohort study","volume":"111","author":"Ao","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.jtho.2025.04.014_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jtho.2025.04.014_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2024.109241","article-title":"Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: a case report","volume":"115","author":"Wang","year":"2024","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.jtho.2025.04.014_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2025.04.014_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.25087","article-title":"A clinical predictive score for postoperative myasthenic crisis","volume":"82","author":"Kanai","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtho.2025.04.014_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JND-230210","article-title":"Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed cell-based assay, radioimmunoprecipitation assay and enzyme-linked immunosorbent Assay1","volume":"11","author":"Diogenes","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jtho.2025.04.014_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","article-title":"The International Association for the Study of Lung Cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (ninth) edition of the TNM classification of malignant tumors","volume":"18","author":"Ruffini","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.04.014_bib15","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jtcvs.2024.04.023","article-title":"Perioperative outcomes and survival of modified subxiphoid video-assisted thoracoscopic surgery thymectomy for T2-3 thymic malignancies: a retrospective comparison study","volume":"168","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.04.014_bib16","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.21037\/gs-21-756","article-title":"Minimally invasive thymectomy for myasthenia gravis: a 7-year retrospective study","volume":"10","author":"Gao","year":"2021","journal-title":"Gland Surg"},{"key":"10.1016\/j.jtho.2025.04.014_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jtho.2025.04.014_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/ejcts\/ezx163","article-title":"Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis","volume":"52","author":"Xue","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2025.04.014_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S0003-4975(03)01139-1","article-title":"Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis","volume":"76","author":"L\u00f3pez-Cano","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.04.014_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jtho.2025.04.014_bib21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jtho.2025.04.014_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12967-023-04421-y","article-title":"Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics","volume":"21","author":"Zhong","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtho.2025.04.014_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116530","article-title":"Preoperative risks of post-operative myasthenic crisis (POMC): a meta-analysis","volume":"407","author":"Akaishi","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jtho.2025.04.014_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2025.04.014_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425007038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:16:32Z","timestamp":1785550592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425007038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1556086425007038"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.04.014","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}